MRKR:NASDAQMarker Therapeutics, Inc. Analysis
Data as of 2026-08-26 - not real-time
$1.52
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Marker Therapeutics, Inc. is priced at $1.52 and its moving averages line up in bearish order, the shorter trailing the longer. The last 30 days have gained 5.6%. Relative strength is 67.9 — approaching overbought — and the MACD signal is bullish. Watch $1.05 as support and $1.60 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 417.5% above today's level.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 77.3%, a beta of 1.08 and a maximum drawdown of 49.3%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 417.5% above today's level.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 77.3%, a beta of 1.08 and a maximum drawdown of 49.3%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
Top Market Events
Benzinga.com1yMarker Therapeutics Corporate Event Calendar NASDAQ:MRKRTrack conference calls, annual meetings, summits,...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading above the 200-day average of 1.42
- MACD momentum is positive
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading above the 200-day average of 1.42
- Analyst targets imply +417.5% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- Negative profit margin of -245.5%
- Analyst targets imply +417.5% versus the current price
- Negative return on equity of -76.9%
Key Metrics & Analysis
Financial Health
Profit Margin-245.51%
P/E Ratio-2.9
ROE-76.87%
ROA-40.47%
P/B Ratio2.1
Op. Cash Flow$-9756497
Free Cash Flow$-6227035
Industry P/E31.2
Technical Analysis
TrendBearish
RSI67.9
Support$1.05
Resistance$1.60
MA 20$1.20
MA 50$1.31
MA 200$1.42
MACDBullish
VolumeIncreasing
Fear & Greed Index93.84
Valuation
Target Price$7.87
Upside/Downside417.54%
GradeFair
TypeBlend
Risk Assessment
Beta1.08
Volatility77.32%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.